Aug 16, 2018 | Featured Insights
Last week, Baron & Budd’s lawyers secured $90 million from AstraZeneca in a resolution that the pharmaceutical company targeted the Texas Medicaid system with a fraudulent marketing scheme for its expensive and powerful atypical antipsychotic drugs Seroquel IR and... 
Jul 25, 2018 | Featured Insights
Firms and lawyers from Texas and Massachusetts joined forces to represent a whistleblower in a major False Claims Act suit against AngioDynamics, a New York-based medical device company. Due to the terms of the settlement, which was announced last week, AngioDynamics...